Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Enhancing Neural Regeneration and Locomotor Recovery with NX Peptide Administration in a Cervical Spinal Cord Injury Rat Model
FY 2020-21
Summary
Spinal cord injury (SCI) results in the loss of sensory and motor function below the site of injury, and there are currently very few effective treatments. The central nervous system (CNS) has limited regenerative capacity, and the loss of neurons that occurs after a SCI is a major barrier to restoring function. The lack of regeneration, paired with excessive inflammation, reduces the ability to heal at the injury site and increases pain. NX is a molecule that has been shown to target various regenerative and inflammatory aspects of SCI. Therefore, NX shows promise as a therapy to provide improved functional recovery for SCI patients. My project aims to examine a cervical rat model of SCI, which has high clinical relevance, as most traumatic SCIs occur at this level of the spine. In this study, NX treatment will be provided over the course of 8 weeks. To evaluate treatment effectiveness, we will look at the distribution of neurons and other CNS cell types at the injury site, changes in inflammation, arm and leg motor recovery, and the degree of pain sensation. Based on previous research conducted on NX, it is expected that it will help improve overall mobility, promote the growth of neurons, reduce inflammation, and decrease the severity of pain experienced. Furthermore, this study will contribute to a collaborative international effort to examine the ability of NX to treat different cases of SCI severity that may be seen in a clinical setting. Overall, this multi-purpose molecule shows great clinical potential in helping improve patients' quality of life. We hope that this treatment will enhance their functional recovery and autonomy.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
449816
Name
Punjani Nayaab
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Enhancing Neural Regeneration and Locomotor Recovery with NX Peptide Administration in a Cervical Spinal Cord Injury Rat Model
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Anatomy; Cervical Spinal Cord Injury; Enzyme-Linked Immunosorbent Assay (Elisa); Immunohistochemistry (Ihc); Inflammation; Neural Regeneration; Neurobehavioural Tests; Nx Peptide; Rat; Sub Commissural Organ (Sco)- Spondin
Abstract
Spinal cord injury (SCI) results in the loss of sensory and motor function below the site of injury, and there are currently very few effective treatments. The central nervous system (CNS) has limited regenerative capacity, and the loss of neurons that occurs after a SCI is a major barrier to restoring function. The lack of regeneration, paired with excessive inflammation, reduces the ability to heal at the injury site and increases pain. NX is a molecule that has been shown to target various regenerative and inflammatory aspects of SCI. Therefore, NX shows promise as a therapy to provide improved functional recovery for SCI patients. My project aims to examine a cervical rat model of SCI, which has high clinical relevance, as most traumatic SCIs occur at this level of the spine. In this study, NX treatment will be provided over the course of 8 weeks. To evaluate treatment effectiveness, we will look at the distribution of neurons and other CNS cell types at the injury site, changes in inflammation, arm and leg motor recovery, and the degree of pain sensation. Based on previous research conducted on NX, it is expected that it will help improve overall mobility, promote the growth of neurons, reduce inflammation, and decrease the severity of pain experienced. Furthermore, this study will contribute to a collaborative international effort to examine the ability of NX to treat different cases of SCI severity that may be seen in a clinical setting. Overall, this multi-purpose molecule shows great clinical potential in helping improve patients' quality of life. We hope that this treatment will enhance their functional recovery and autonomy.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Punjani, Nayaab
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~